Data Presented To FDA Panel Show TAXUS Drug-Eluting Stents as Safe as Bare-Metal Stents and Far More Effective in (PR Newswire via Yahoo! Finance)
Boston Scientific Corporation today presented data on its long- term randomized clinical trials to a special U.S. Food and Drug Administration panel, showing that the TAXUS paclitaxel-eluting coronary stent is as safe as bare-metal stents and far more effective in keeping arteries open and reducing the need for repeat procedures.

FDA Approves First Generic Ondansetron Injection (DrugDiscoveryOnline)
The U. S. Food and Drug Administration (FDA) recently approved first generic versions of Zofran (Ondansetron) Injection and Zofran (Ondansetron) Injection Premixed

Real-World Taxus(R) Stent Data Confirm Favorable Outcomes for Patients With Complex Coronary Artery Disease (Boursorama)
NATICK, Mass. and GAITHERSBURG, Md., Dec. 7 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today presented data on its 7,000- patient ARRIVE I and II registries of real-world patients -- including those with complex lesions -- to a special U.S. Food and Drug Administration (FDA) panel.